Skip Navigation


Rheumatology Advance Access originally published online on April 25, 2007
Rheumatology 2007 46(7):1071-1075; doi:10.1093/rheumatology/kem067
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
46/7/1071    most recent
kem067v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Przybysz, M.
Right arrow Articles by Katnik-Prastowska, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Przybysz, M.
Right arrow Articles by Katnik-Prastowska, I.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Synovial fibronectin fragmentation and domain expressions in relation to rheumatoid arthritis progression

M. Przybysz, K. Borysewicz1, J. Szechinski1 and I. Katnik-Prastowska

Department of Chemistry and Immunochemistry, Medical University, Bujwida 44a, 50-345 Wroclaw and 1Department of Rheumatology, Medical University, Wroclaw, Poland, Wisniowa 36, 53-137 Wroclaw, Poland.

Correspondence to: Iwona Katnik-Prastowska, Department of Chemistry and Immunochemistry, Wroclaw Medical University, Bujwida 44a, 50-345 Wroclaw, Poland. E-mail: iwona{at}immchem.am.wroc.pl


   Abstract

Objective. To determine whether the expression of some fibronectin (FN) domains and a degree of FN degradation are associated with the progression of rheumatoid arthritis (RA).

Methods. Based on the radiographs of the hands of RA patients, three groups of synovial fluid and plasma samples were distinguished: (i) those with early radiological changes, (ii) established and (iii) late progressive radiological changes. The expressions of FN domains were determined by ELISA using appropriate domain-specific monoclonal antibodies. FN fragmentation was analysed by immunoblotting.

Results. In the early RA group, synovial FN was found to be totally degraded to a mixture of FN fragments. In the established group, it consisted of a portion of intact FN molecules and a smaller part of FN fragments, whereas in the late group the synovial FN immunoblotting pattern was similar to that of intact FN. The FN fragmentation was accompanied by decreases in FN immune reactivity with monoclonal antibodies specific to the collagen, fibrin and C-terminal FN domains. In the blood plasma of all studied groups of RA patients, the FN immunopattern was analogous to that in normal plasma. However, the expressions of the plasma FN domains were higher than those of healthy individuals.

Conclusions. Profound degradation of FN and low collagen, fibrin and C-terminal domain expressions in FN were only associated with early destructive changes observed in radiographs of the RA patients’ hands.

KEY WORDS: Fibronectin, Fibronectin fragments, Fibronectin domains, Rheumatoid arthritis, Synovial fluid

Submitted 4 December 2006; revised version accepted 20 February 2007.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.